Use of sacubitril/valsartan in patients with heart failure: evidence from the real world.

Luis Fernando Valladales-RestrepoNicolás Sánchez-RamírezAndrés Felipe Usma-ValenciaSantiago Velásquez-QuiramaManuela Henao-MartínezJorge Alejandro Castro-RodriguezAndrés Gaviria-MendozaManuel Enrique Machado-DuqueJorge Enrique Machado-Alba

Published in: Expert opinion on pharmacotherapy (2023)

The persistence of treatment 1 year after starting sacubitril/valsartan was not high, and a small proportion of patients reached the target dose of the drug. Nontitration of the drug dose was common.

Keyphrases

ejection fraction
end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
emergency department
drug induced
smoking cessation
replacement therapy